PARTNERING CONTACT "IMPROVING MILLIONS OF LIVES IS IMPORTANT TO ME AS A SCIENTIST" Nurzian Ismail - Principal scientist WORLD'S FIRST GENERIC TO LEADING GNRH ANALOGUE WITH CONTROLLED RELEASE Xbrane is pioneering high demand biosimilars. CONTROLLED RELEASE GENERICS OUTPERFORMING INDUSTRY STANDARDS BY DEVELOPING BIOSIMILARS WITH NEXT GENERATION TECHNOLOGY Enabling access to critical medication for life critical diseases BIOSIMILARS INVESTORS LATEST NEWS Xbrane Biopharma AB bjuder in till bolagspresentation 12 oktober i Stockholm Read more >> Xbrane Biopharma AB: Xbrane deltar på Carnegie Nordic HealthCare Day i New York, 5 december Read more >> Xbrane Biopharma AB: Xbrane attends Carnegie Nordic HealthCare Day in New York, 5 December Read more >> Xbrane bekräftar order av Spherotide till ett värde av 8,5 MSEK och över 10 000 doser sålda Read more >> Xbrane confirms order of Spherotide to value of SEK 8.5 million and more than 10,000 doses sold Read more >> News & Events >> EVENTS 09 JAN 2017 J.P. Morgan 35th Annual Healthcare Conference, January 9-12 Read more >> OUR UNIQUE STRENGTHS Addressing increasing global demands An unique platform technology Our vision Our pipeline Xbrane Biopharma Banvaktsvägen 22 17148 Solna Sweden info@xbrane.com About Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. The segment have a high entry barrier, driven by high production complexity and the need of specific Know- How. Links Technologies Products Investors News & Events Partnering Career Social media X SUBSCRIBE TO XBRANE BIOPHARMA NEWS AND PRESS RELEASES SUBSCRIBE